Eris Lifesciences - Niche Launches To Aid Growth Over The Medium Term: Motilal Oswal

BQ Prime’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BQ Prime’s subscribers an opportunity to expand their understanding of companies, sectors and the economy..Motilal Oswal Report.The Dydrogesterone market is at an interesting phase, with an improvement in demand due to better access, affordability, and technical superiority over Progesterone. The initial response for Eris Lifesciences Ltd.’s product (Drolute) has been encouraging, with sales of Rs 44 million since its launch in January 2022. We expect this product to aid 2-3% YoY growth for Eris Lifesciences in FY23. While the insulin market has been steady, with seven players in India till FY18, Eris Lifesciences’ insulin product (Xsulin) marks the entry of the third new player since then. Given its enhanced product offering and brand recall in the diabetes space, we expect the company to gain healthy traction in Xsulin in coming years..Click on the attachment to read the full report:.DISCLAIMERThis report is authored by an external party. BQ Prime does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BQ Prime..Users have no license to copy, modify, or distribute the content without permission of the Original Owner.

Eris Lifesciences - Niche Launches To Aid Growth Over The Medium Term: Motilal Oswal

Eris Lifesciences - Niche Launches To Aid Growth Over The Medium Term: Motilal Oswal

Choose a plan